[go: up one dir, main page]

Liu et al., 2020 - Google Patents

PRKAR1A deficiency impedes hypertrophy and reduces heart size

Liu et al., 2020

View PDF @Full View
Document ID
2765041411899705429
Author
Liu Y
Xia P
Chen J
Bandettini W
Kirschner L
Stratakis C
Cheng Z
Publication year
Publication venue
Physiological Reports

External Links

Snippet

Protein kinase A (PKA) activity is pivotal for proper functioning of the human heart, and its dysregulation has been implicated in a variety of cardiac pathologies. PKA regulatory subunit 1α (R1α, encoded by the PRKAR1A gene) is highly expressed in the heart, and …
Continue reading at physoc.onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Similar Documents

Publication Publication Date Title
Bryant et al. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
Ferrara-Romeo et al. The mTOR pathway is necessary for survival of mice with short telomeres
Liu et al. PRKAR1A deficiency impedes hypertrophy and reduces heart size
Penfold et al. CAMKK2 promotes prostate cancer independently of AMPK via increased lipogenesis
Hediger et al. Molecular physiology of urate transport
García‐Rúa et al. Endolysosomal two‐pore channels regulate autophagy in cardiomyocytes
Xiong et al. Advanced maternal age‐associated SIRT1 deficiency compromises trophoblast epithelial− mesenchymal transition through an increase in vimentin acetylation
Eskelinen et al. Inhibition of autophagy in mitotic animal cells
Zhou et al. The cerebral cavernous malformation pathway controls cardiac development via regulation of endocardial MEKK3 signaling and KLF expression
Sussman et al. Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1
Celton-Morizur et al. The insulin/Akt pathway controls a specific cell division program that leads to generation of binucleated tetraploid liver cells in rodents
Rozic et al. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis
Ruan et al. Inducible and cardiac specific PTEN inactivation protects ischemia/reperfusion injury
Mundigl et al. Amphiphysin I antisense oligonucleotides inhibit neurite outgrowth in cultured hippocampal neurons
US9533002B2 (en) Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-β
Liu et al. Vitamin D mediates its action in human colon carcinoma cells in a calcium‐sensing receptor‐dependent manner: downregulates malignant cell behavior and the expression of thymidylate synthase and survivin and promotes cellular sensitivity to 5‐FU
US20080312267A1 (en) Diagnosis and Treatment of Diseases Arising from Defects in the Tuberous Sclerosis Pathway
Tang et al. Developmental consequences of abnormal folate transport during murine heart morphogenesis
Kang et al. Phospholipase D1 has a pivotal role in interleukin-1β-driven chronic autoimmune arthritis through regulation of NF-κB, hypoxia-inducible factor 1α, and FoxO3a
CN102224254A (en) Sirt4 and uses thereof
Kurbegovic et al. Acute kidney injury induces hallmarks of polycystic kidney disease
Liu et al. Chloride intracellular channel 1 (CLIC1) contributes to modulation of cyclic AMP‐activated whole‐cell chloride currents in human bronchial epithelial cells
Zhao Endoplasmic reticulum stress in maternal diabetes‐induced cardiac malformations during critical cardiogenesis period
US20050070567A1 (en) Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
Yu et al. Inhibition of sarcoplasmic reticular function by chronic interleukin‐6 exposure via iNOS in adult ventricular myocytes